Document is current
Any future updates will be listed below
-
Authors
Allegretti, Jessica R. http://orcid.org/0000-0003-3585-2425
Brady, Jessica H.
Wicker, Ann
Latymer, Mark
Wells, Alvin http://orcid.org/0000-0001-7311-7689
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 20 December 2023
Accepted: 7 February 2024
First Online: 11 March 2024
Declarations
:
: Jessica R. Allegretti reports consulting fees from AbbVie Inc, Adiso Therapeutics, Bristol-Myers Squibb, Ferring, Finch Therapeutics, GlaxoSmithKline, Janssen Pharmaceuticals, Merck, Pfizer, Roivant Sciences and Seres Therapeutics; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AbbVie Inc, Bristol-Myers Squibb, and Janssen Pharmaceuticals; payment for expert testimony from Finch Therapeutics; and participation on a Data Safety Monitoring Board or Advisory Board for Merck. Jessica H. Brady has no disclosures to report. Mark Latymer and Ann Wicker are full-time employees of and hold stock or options in Pfizer. Alvin Wells reports payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AbbVie Inc, Alexion Pharmaceuticals, Amgen Inc, AstraZeneca, Aurinia Pharmaceuticals Inc, Eli Lilly and Company, GSK plc and UCB.
: This article is based on previously conducted studies and other sources; it does not contain any studies with human participants or animals performed by any of the authors.
